FibroBiologics, Inc. (FBLG): Cash & Equivalents
$4.89M
As of 2025-12-31
$3.52M
As of 2026-06-30
+29.3%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.89M | -65.0% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $13.98M | +52.6% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $9.16M | +304.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $2.27M | n/a | 2024-02-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $4.89M | -65.0% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $0 | n/a |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $7.03M | -28.8% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $5.53M | +14.6% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $7.56M | -85.2% |
| Nanoviricides, Inc. (NNVC) | 2026-06-30 | $2.79M | +79.3% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $8.51M | +47.0% |
| Lunai Bioworks Inc. (LNAI) | 2026-06-30 | $1.71M | n/m |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $3.24M | +0.2% |
Compare FBLG, MAIA, COCP, CANF side by side · Screen every company in Pharmaceutical Preparations ↗